In mice models of cardiac hypertrophy and in in vitro phenylephrine-treated cardiomyocytes, ATGL levels were found to be suppressed (Gao et al. 2015), which regulated cardiac dysfunction and remodeling by affecting lipid and energy metabolism. Here, PNPLA2 is linked to cardiac hypertrophy.